OEP PHARMA
Dead / Abandoned — Abandoned — no statement of use filed (as of 12 Sept 2022)
What this means for you
This application is over — abandoned 12 Sept 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90318022
- Mark type
- Design + words
- Filed
- 13 Nov 2020
- Published for opposition
- 15 Jun 2021
- Abandoned
- 12 Sept 2022
- Attorney of record
- Nicole B. Rackiewicz
Goods and services
- Class 005 — Pharmaceuticals: Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical products for the prevention and treatment of cancer; Therapeutic pharmaceuticals for the treatment of cancer, cardiovascular diseases, metabolic diseases, musculoskeletal diseases, infectious diseases, and neurodegenerative diseases; Pharmaceutical preparations for the treatment of hyperlipidemia; Local anesthetics; Drug delivery agents in the form of a coating for tablets and capsules that facilitate the delivery of a wide range of pharmaceuticals; Medicinal preparations of the treatment of infectious diseases and for use in oncology; Anesthetics; Anesthetics for surgical purposes; Pharmaceutical preparations for treating diabetes; Anti-diabetic pharmaceuticals; Cardiovascular agents for medical purposes; Drug delivery agents in the form of transdermal patches, coatings for tablets, and synthetic materials that facilitate the delivery of pharmaceutical preparations; Skeletal muscle relaxants; Pharmaceutical preparations for treating hypertension; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations for the treatment of cancer, cardiovascular diseases, metabolic diseases, musculoskeletal diseases, infectious diseases, and neurodegenerative diseases; Anesthetics for surgical and non-surgical use; Pharmaceuticals, namely, lipid lowering agents; Pharmaceutical preparations for use in chemotherapy; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Transdermal patches for use in the treatment of neurodegenerative disease; Cardiovascular pharmaceuticals; Hypolipidemic agents; Anesthetics for surgical use; Pain relief medication; Pharmaceutical products for the treatment of cancer; Hypolipidemic agents
Owner
- Orient Europharma Co., Ltd., Taipei, TW
- Orient Europharma Co., Ltd., Taipei, TW
Prosecution history
- 12 Sept 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 12 Sept 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 01 Feb 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Jan 2022 — SOU EXTENSION 1 GRANTED
- 28 Jan 2022 — SOU EXTENSION 1 FILED
- 28 Jan 2022 — SOU TEAS EXTENSION RECEIVED
- 10 Aug 2021 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Jun 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Jun 2021 — PUBLISHED FOR OPPOSITION
- 26 May 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 May 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 10 May 2021 — EXAMINER'S AMENDMENT ENTERED
- 10 May 2021 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 10 May 2021 — EXAMINERS AMENDMENT E-MAILED
- 10 May 2021 — EXAMINERS AMENDMENT -WRITTEN